Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall

Cadrenal Therapeutics

13/08/2026 22:04

Overview
US biopharma firm's Q2 net loss narrowed yr/yr as operating expenses declined
Company highlighted positive Phase 2 CAD-1005 data and launched strategic partnering process
Cash expected to fund operations through Q1 2027; further funding needed for clinical trials

Outlook
Company expects current cash to fund operations through Q1 2027
Cadrenal does not plan to start clinical trials without sufficient funding in place
Company is pursuing strategic partnerships and non-dilutive grants to advance its programs

Result Drivers
LOWER OPERATING EXPENSES - Q2 operating expenses declined yr/yr, driven by reduced research and development and general and administrative costs
CLINICAL PROGRESS - Positive Phase 2 CAD-1005 data presented, showing over 25% reduction in thrombotic events
CAPITAL-EFFICIENT STRATEGY - Co launched strategic partnering process and is pursuing non-dilutive grants and out-licensing to fund development

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$1.14
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cadrenal Therapeutics Inc is $13.00, about 606.5% above its August 12 closing price of $1.84

Reuters Recommended Reads
Aug 13 - Artelo Biosciences Q2 net loss narrows as R&D expenses fall
Aug 13 - Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Aug 13 - Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)